Review



rat tfa  (MedChemExpress)


Bioz Verified Symbol MedChemExpress is a verified supplier
Bioz Manufacturer Symbol MedChemExpress manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
  • 92

    Structured Review

    MedChemExpress rat tfa
    (A) Protein levels of RAMP1 in Control and H/R groups with and <t>without</t> <t>CGRP</t> agonist. (B) Relative cell activity was determined by CCK-8 assay of RAMP1 in the control and H/R groups using a CGRP agonist. (C) CCK-8 assay was performed using CGRP agonists, YAP inhibitors, and agonists in H/R. (D) CCK-8 assay was performed using a CGRP agonist combined with an ERK inhibitor or agonist in H/R. (E) CCK-8 experiments were performed using ERK inhibitors in combination with YAP inhibitors or agonists in H/R. (F) CCK-8 assays were performed using ERK agonists combined with a YAP inhibitor or agonist in H/R. (G) Statistical analysis of flow cytometry to detect the proportion of apoptosis in H/R with a CGRP agonist, YAP inhibitor and agonist, and ERK inhibitor and agonist. (H) Statistical data in H/R, ERK inhibitor combined with YAP inhibitor or agonist were used to detect the proportion of apoptosis by flow cytometry. (I) Statistical data in H/R using ERK agonists combined with YAP inhibitors or agonists to detect the proportion of apoptosis. CGRP agonist: Caltonin gene-related peptide (CGRP) II, rat <t>TFA,</t> ERK agonist (C16-PAF); ERK inhibitor (SCH772984); YAP agonist (PY-60); and YAP inhibitor (Verteporfin). The cells were treated with apoptosis pathway inhibitors and subjected to 6 h of reperfusion after hypoxia. All data are presented as the mean ± SD. * p <0.05, ** p <0.01, *** p <0.001 using Student’s two-tailed t-test. CCK-8, cell counting Kit-8; CGRP agonist, caltonin gene-related peptide agonist; HIRI, hepatic ischemia-reperfusion injury.
    Rat Tfa, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 92/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/rat tfa/product/MedChemExpress
    Average 92 stars, based on 1 article reviews
    rat tfa - by Bioz Stars, 2026-03
    92/100 stars

    Images

    1) Product Images from "RAMP1 Protects Hepatocytes against Ischemia-reperfusion Injury by Inhibiting the ERK/YAP Pathway"

    Article Title: RAMP1 Protects Hepatocytes against Ischemia-reperfusion Injury by Inhibiting the ERK/YAP Pathway

    Journal: Journal of Clinical and Translational Hepatology

    doi: 10.14218/JCTH.2023.00339

    (A) Protein levels of RAMP1 in Control and H/R groups with and without CGRP agonist. (B) Relative cell activity was determined by CCK-8 assay of RAMP1 in the control and H/R groups using a CGRP agonist. (C) CCK-8 assay was performed using CGRP agonists, YAP inhibitors, and agonists in H/R. (D) CCK-8 assay was performed using a CGRP agonist combined with an ERK inhibitor or agonist in H/R. (E) CCK-8 experiments were performed using ERK inhibitors in combination with YAP inhibitors or agonists in H/R. (F) CCK-8 assays were performed using ERK agonists combined with a YAP inhibitor or agonist in H/R. (G) Statistical analysis of flow cytometry to detect the proportion of apoptosis in H/R with a CGRP agonist, YAP inhibitor and agonist, and ERK inhibitor and agonist. (H) Statistical data in H/R, ERK inhibitor combined with YAP inhibitor or agonist were used to detect the proportion of apoptosis by flow cytometry. (I) Statistical data in H/R using ERK agonists combined with YAP inhibitors or agonists to detect the proportion of apoptosis. CGRP agonist: Caltonin gene-related peptide (CGRP) II, rat TFA, ERK agonist (C16-PAF); ERK inhibitor (SCH772984); YAP agonist (PY-60); and YAP inhibitor (Verteporfin). The cells were treated with apoptosis pathway inhibitors and subjected to 6 h of reperfusion after hypoxia. All data are presented as the mean ± SD. * p <0.05, ** p <0.01, *** p <0.001 using Student’s two-tailed t-test. CCK-8, cell counting Kit-8; CGRP agonist, caltonin gene-related peptide agonist; HIRI, hepatic ischemia-reperfusion injury.
    Figure Legend Snippet: (A) Protein levels of RAMP1 in Control and H/R groups with and without CGRP agonist. (B) Relative cell activity was determined by CCK-8 assay of RAMP1 in the control and H/R groups using a CGRP agonist. (C) CCK-8 assay was performed using CGRP agonists, YAP inhibitors, and agonists in H/R. (D) CCK-8 assay was performed using a CGRP agonist combined with an ERK inhibitor or agonist in H/R. (E) CCK-8 experiments were performed using ERK inhibitors in combination with YAP inhibitors or agonists in H/R. (F) CCK-8 assays were performed using ERK agonists combined with a YAP inhibitor or agonist in H/R. (G) Statistical analysis of flow cytometry to detect the proportion of apoptosis in H/R with a CGRP agonist, YAP inhibitor and agonist, and ERK inhibitor and agonist. (H) Statistical data in H/R, ERK inhibitor combined with YAP inhibitor or agonist were used to detect the proportion of apoptosis by flow cytometry. (I) Statistical data in H/R using ERK agonists combined with YAP inhibitors or agonists to detect the proportion of apoptosis. CGRP agonist: Caltonin gene-related peptide (CGRP) II, rat TFA, ERK agonist (C16-PAF); ERK inhibitor (SCH772984); YAP agonist (PY-60); and YAP inhibitor (Verteporfin). The cells were treated with apoptosis pathway inhibitors and subjected to 6 h of reperfusion after hypoxia. All data are presented as the mean ± SD. * p <0.05, ** p <0.01, *** p <0.001 using Student’s two-tailed t-test. CCK-8, cell counting Kit-8; CGRP agonist, caltonin gene-related peptide agonist; HIRI, hepatic ischemia-reperfusion injury.

    Techniques Used: Control, Activity Assay, CCK-8 Assay, Flow Cytometry, Two Tailed Test, Cell Counting



    Similar Products

    93
    TargetMol cgrp (83-119), rat tfa
    Cgrp (83 119), Rat Tfa, supplied by TargetMol, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/cgrp (83-119), rat tfa/product/TargetMol
    Average 93 stars, based on 1 article reviews
    cgrp (83-119), rat tfa - by Bioz Stars, 2026-03
    93/100 stars
      Buy from Supplier

    90
    TargetMol nude mice
    Nude Mice, supplied by TargetMol, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/nude mice/product/TargetMol
    Average 90 stars, based on 1 article reviews
    nude mice - by Bioz Stars, 2026-03
    90/100 stars
      Buy from Supplier

    92
    MedChemExpress rat tfa
    (A) Protein levels of RAMP1 in Control and H/R groups with and <t>without</t> <t>CGRP</t> agonist. (B) Relative cell activity was determined by CCK-8 assay of RAMP1 in the control and H/R groups using a CGRP agonist. (C) CCK-8 assay was performed using CGRP agonists, YAP inhibitors, and agonists in H/R. (D) CCK-8 assay was performed using a CGRP agonist combined with an ERK inhibitor or agonist in H/R. (E) CCK-8 experiments were performed using ERK inhibitors in combination with YAP inhibitors or agonists in H/R. (F) CCK-8 assays were performed using ERK agonists combined with a YAP inhibitor or agonist in H/R. (G) Statistical analysis of flow cytometry to detect the proportion of apoptosis in H/R with a CGRP agonist, YAP inhibitor and agonist, and ERK inhibitor and agonist. (H) Statistical data in H/R, ERK inhibitor combined with YAP inhibitor or agonist were used to detect the proportion of apoptosis by flow cytometry. (I) Statistical data in H/R using ERK agonists combined with YAP inhibitors or agonists to detect the proportion of apoptosis. CGRP agonist: Caltonin gene-related peptide (CGRP) II, rat <t>TFA,</t> ERK agonist (C16-PAF); ERK inhibitor (SCH772984); YAP agonist (PY-60); and YAP inhibitor (Verteporfin). The cells were treated with apoptosis pathway inhibitors and subjected to 6 h of reperfusion after hypoxia. All data are presented as the mean ± SD. * p <0.05, ** p <0.01, *** p <0.001 using Student’s two-tailed t-test. CCK-8, cell counting Kit-8; CGRP agonist, caltonin gene-related peptide agonist; HIRI, hepatic ischemia-reperfusion injury.
    Rat Tfa, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 92/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/rat tfa/product/MedChemExpress
    Average 92 stars, based on 1 article reviews
    rat tfa - by Bioz Stars, 2026-03
    92/100 stars
      Buy from Supplier

    90
    Thermo Fisher tfa ($54/mol, rat ld50 oral values 200−400 mg/kg)
    (A) Protein levels of RAMP1 in Control and H/R groups with and <t>without</t> <t>CGRP</t> agonist. (B) Relative cell activity was determined by CCK-8 assay of RAMP1 in the control and H/R groups using a CGRP agonist. (C) CCK-8 assay was performed using CGRP agonists, YAP inhibitors, and agonists in H/R. (D) CCK-8 assay was performed using a CGRP agonist combined with an ERK inhibitor or agonist in H/R. (E) CCK-8 experiments were performed using ERK inhibitors in combination with YAP inhibitors or agonists in H/R. (F) CCK-8 assays were performed using ERK agonists combined with a YAP inhibitor or agonist in H/R. (G) Statistical analysis of flow cytometry to detect the proportion of apoptosis in H/R with a CGRP agonist, YAP inhibitor and agonist, and ERK inhibitor and agonist. (H) Statistical data in H/R, ERK inhibitor combined with YAP inhibitor or agonist were used to detect the proportion of apoptosis by flow cytometry. (I) Statistical data in H/R using ERK agonists combined with YAP inhibitors or agonists to detect the proportion of apoptosis. CGRP agonist: Caltonin gene-related peptide (CGRP) II, rat <t>TFA,</t> ERK agonist (C16-PAF); ERK inhibitor (SCH772984); YAP agonist (PY-60); and YAP inhibitor (Verteporfin). The cells were treated with apoptosis pathway inhibitors and subjected to 6 h of reperfusion after hypoxia. All data are presented as the mean ± SD. * p <0.05, ** p <0.01, *** p <0.001 using Student’s two-tailed t-test. CCK-8, cell counting Kit-8; CGRP agonist, caltonin gene-related peptide agonist; HIRI, hepatic ischemia-reperfusion injury.
    Tfa ($54/Mol, Rat Ld50 Oral Values 200−400 Mg/Kg), supplied by Thermo Fisher, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/tfa ($54/mol, rat ld50 oral values 200−400 mg/kg)/product/Thermo Fisher
    Average 90 stars, based on 1 article reviews
    tfa ($54/mol, rat ld50 oral values 200−400 mg/kg) - by Bioz Stars, 2026-03
    90/100 stars
      Buy from Supplier

    Image Search Results


    (A) Protein levels of RAMP1 in Control and H/R groups with and without CGRP agonist. (B) Relative cell activity was determined by CCK-8 assay of RAMP1 in the control and H/R groups using a CGRP agonist. (C) CCK-8 assay was performed using CGRP agonists, YAP inhibitors, and agonists in H/R. (D) CCK-8 assay was performed using a CGRP agonist combined with an ERK inhibitor or agonist in H/R. (E) CCK-8 experiments were performed using ERK inhibitors in combination with YAP inhibitors or agonists in H/R. (F) CCK-8 assays were performed using ERK agonists combined with a YAP inhibitor or agonist in H/R. (G) Statistical analysis of flow cytometry to detect the proportion of apoptosis in H/R with a CGRP agonist, YAP inhibitor and agonist, and ERK inhibitor and agonist. (H) Statistical data in H/R, ERK inhibitor combined with YAP inhibitor or agonist were used to detect the proportion of apoptosis by flow cytometry. (I) Statistical data in H/R using ERK agonists combined with YAP inhibitors or agonists to detect the proportion of apoptosis. CGRP agonist: Caltonin gene-related peptide (CGRP) II, rat TFA, ERK agonist (C16-PAF); ERK inhibitor (SCH772984); YAP agonist (PY-60); and YAP inhibitor (Verteporfin). The cells were treated with apoptosis pathway inhibitors and subjected to 6 h of reperfusion after hypoxia. All data are presented as the mean ± SD. * p <0.05, ** p <0.01, *** p <0.001 using Student’s two-tailed t-test. CCK-8, cell counting Kit-8; CGRP agonist, caltonin gene-related peptide agonist; HIRI, hepatic ischemia-reperfusion injury.

    Journal: Journal of Clinical and Translational Hepatology

    Article Title: RAMP1 Protects Hepatocytes against Ischemia-reperfusion Injury by Inhibiting the ERK/YAP Pathway

    doi: 10.14218/JCTH.2023.00339

    Figure Lengend Snippet: (A) Protein levels of RAMP1 in Control and H/R groups with and without CGRP agonist. (B) Relative cell activity was determined by CCK-8 assay of RAMP1 in the control and H/R groups using a CGRP agonist. (C) CCK-8 assay was performed using CGRP agonists, YAP inhibitors, and agonists in H/R. (D) CCK-8 assay was performed using a CGRP agonist combined with an ERK inhibitor or agonist in H/R. (E) CCK-8 experiments were performed using ERK inhibitors in combination with YAP inhibitors or agonists in H/R. (F) CCK-8 assays were performed using ERK agonists combined with a YAP inhibitor or agonist in H/R. (G) Statistical analysis of flow cytometry to detect the proportion of apoptosis in H/R with a CGRP agonist, YAP inhibitor and agonist, and ERK inhibitor and agonist. (H) Statistical data in H/R, ERK inhibitor combined with YAP inhibitor or agonist were used to detect the proportion of apoptosis by flow cytometry. (I) Statistical data in H/R using ERK agonists combined with YAP inhibitors or agonists to detect the proportion of apoptosis. CGRP agonist: Caltonin gene-related peptide (CGRP) II, rat TFA, ERK agonist (C16-PAF); ERK inhibitor (SCH772984); YAP agonist (PY-60); and YAP inhibitor (Verteporfin). The cells were treated with apoptosis pathway inhibitors and subjected to 6 h of reperfusion after hypoxia. All data are presented as the mean ± SD. * p <0.05, ** p <0.01, *** p <0.001 using Student’s two-tailed t-test. CCK-8, cell counting Kit-8; CGRP agonist, caltonin gene-related peptide agonist; HIRI, hepatic ischemia-reperfusion injury.

    Article Snippet: YAP phosphorylation inhibitor: Truli (E1061, Selleck, 0.2 nm) and PY-60 (HY-141644, MCE; 1.6 µm; 10 mg/kg for mice in vivo , i.p. ); ERK phosphorylation inhibitor: Temuterkib (HY-101494, MCE; 5 nm) and SCH772984 (HY-50846, MCE; 300 nm, 5 mg/kg for mice in vivo , i.p. ); ERK agonist: C16-PAF(HY-108635, MCE, 1 µm , ); STAT3 inhibitor : Sttatic (HY-13818, MCE; IC50:10 µm); p-AKT inhibitor: MK2206 (HY-10358, MCE; 65 nm); Caspase-3 inhibitor: Z-VAD (HY-16658B, MCE; 10 µm ; 10 mg/kg for mice in vivo , i.p. ); CGRP agonist: Calcitonin Gene Related Peptide (CGRP) II, rat TFA (HY-P1913A , MCE; 83 µm ); Verteporfin (HY-B0146, MCE; 5 µm ).

    Techniques: Control, Activity Assay, CCK-8 Assay, Flow Cytometry, Two Tailed Test, Cell Counting